日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of first-line sintilimab plus anlotinib versus chemotherapy for metastatic non-small cell lung cancer: a phase II, open-label, randomized controlled trial

一线信迪利单抗联合安罗替尼对比化疗治疗转移性非小细胞肺癌的疗效和安全性:一项II期、开放标签、随机对照试验

Chu, Tianqing; Zhong, Hua; Yu, Zhuang; Wang, Jing; Zhao, Yanqiu; Mu, Xiaoqian; Yu, Xinmin; Shi, Xun; Shi, Qingming; Guan, Maojing; Ding, Cuimin; Geng, Nan; Qian, Jialin; Han, Baohui

Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial

托瑞普利单抗联合化疗作为广泛期小细胞肺癌的一线治疗:EXTENTORCH III期随机临床试验

Cheng, Ying; Zhang, Wei; Wu, Lin; Zhou, Caicun; Wang, Donglin; Xia, Bing; Bi, Minghong; Fu, Xiuhua; Li, Chong; Lv, Dongqing; Zhao, Yanqiu; Chen, Gongyan; Yi, Tienan; Huang, Jianan; Li, Min; Yang, Runxiang; Huang, Xiaoping; Wang, Ye; Zhang, Mingjun; Pan, Yueyin; Sun, Yilan; Hu, Sheng; Zhang, Xiqin; Zhou, Min; Fang, Jian; Jin, Faguang; Liu, Yunpeng; Li, Yinyin; Zhang, Zhihong; Hu, Jie; Liu, Laiyu; Wang, Rui; Li, Yan; Gu, Kangsheng; Ding, Cuimin; Fan, Qingxia; Zhang, Guojun; Chen, Yongxing; Jiang, Liyan; Zheng, Wei-E; Chen, Shaoshui; Huang, Cheng; Han, Zhigang; Yang, Hong; Wang, Jianfang; Wang, Baocheng; Wu, Huita; Bao, Yongxing; Li, Manxiang; Luo, Xianming; Gu, Shanshan; Yu, Wenbo; Xu, Kai; Zhang, Simo; Yu, Jianjun

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

奥希替尼联合安罗替尼治疗获得性EGFR T790M突变的晚期非小细胞肺癌:一项多中心II期临床研究及ctDNA分析结果

Wang, Xinyue; Li, Zhaona; Wang, Liuchun; Liang, Yan; Huang, Chun; Chen, Peng; Huang, Dingzhi; Song, Xia; Ding, Cuimin; Wang, Changli; Jiang, Richeng

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study

程序性死亡配体1肿瘤比例评分在预测PD-1/PD-L1抗体疗法治疗晚期非小细胞肺癌患者的安全性和有效性中的应用:一项回顾性、多中心、观察性研究

Shi, Yuequan; Liu, Xiaoyan; Liu, Anwen; Fang, Jian; Meng, Qingwei; Ding, Cuimin; Ai, Bin; Gu, Yangchun; Zhang, Cuiying; Zhou, Chengzhi; Wang, Yan; Shui, Yongjie; Yu, Siyuan; Zhang, Dongming; Liu, Jia; Zhang, Haoran; Zhou, Qing; Gao, Xiaoxing; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Xu, Yan; Wang, Mengzhao

The inhibitory effect of M2 macrophage-derived exosomes on gefitinib resistant lung adenocarcinoma cells through the MIF/TIMP1/CD74 axis.

M2巨噬细胞来源的外泌体通过MIF/TIMP1/CD74轴对吉非替尼耐药肺腺癌细胞的抑制作用

Peng Jingcui, Zhang Yan, Li Bin, He Xin, Ding Cuimin, Hu Wenxia

Efficacy and safety of finotonlimab plus docetaxel vs. docetaxel in previously treated advanced squamous cell non-small-cell lung cancer: a randomized, double-blinded, phase III trial

芬诺利单抗联合多西他赛对比单用多西他赛治疗既往接受过治疗的晚期鳞状非小细胞肺癌的疗效和安全性:一项随机、双盲、III期试验

Han, Baohui; Wu, Lin; Yang, Runxiang; Wu, Hongbo; Li, Wei; Yu, Yan; Zhang, Mingjuan; Sun, Hongmei; Chu, Tianqing; Zhong, Fukuan; Fang, Yong; Wu, Rong; Bian, Tao; Guo, Xiaoqing; Sun, Meili; Zhang, Yanming; Liu, Lianke; Liu, Xuewen; Pan, Yueyin; Jiang, Ou; Wei, Zonghui; Lin, Haifeng; Guo, Wei; Fang, Jian; Wang, Jialei; Ding, Cuimin; Hu, Yanping; Ye, Feng; Zhuang, Wu; Ye, Shucheng; Wang, Lihong; Huang, Zhe; Liu, Chang; Yang, Ling; Wang, Jinling; Xie, Liangzhi

Comparative effectiveness of pembrolizumab-chemotherapy versus chemotherapy with/without bevacizumab in unresectable, locally advanced or metastatic non-small cell lung cancer: a Chinese multicenter real-world analysis emphasizing PD-L1-negative populations

帕博利珠单抗联合化疗与贝伐珠单抗联合/不联合化疗治疗不可切除、局部晚期或转移性非小细胞肺癌的疗效比较:一项以PD-L1阴性人群为重点的中国多中心真实世界分析

Guo, Xiaobei; Zhang, Hui; Shi, Yuequan; He, Qi; Liu, Anwen; Zeng, Zhimin; Wang, Jinghui; Wei, Song; Zhang, Tong; Ding, Cuimin; Fang, Jian; Chen, Xiaoling; Van Schil, Paul; Zhang, Haoran; Pang, Junyi; Chen, Minjiang; Zhao, Jing; Zhong, Wei; Huo, Zhen; Xu, Yan; Wang, Mengzhao

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial

贝伐珠单抗生物类似药SIBP04与贝伐珠单抗(阿瓦斯汀®)一线治疗局部晚期或转移性非鳞状非小细胞肺癌的疗效和安全性比较:一项随机、双盲、3期临床试验

Shi, Yuankai; Bi, Minghong; Li, Qingshan; Wang, Guolei; Chen, Jianhua; Li, Mingjun; Shi, Jianhua; Mei, Jiazhuan; Ji, Yinghua; Xia, Qingdi; Feng, Yuanqing; Xu, Shufeng; Zhang, Tongmei; Gao, Xiaohui; Tang, Shubin; Weng, Jie; Cao, Zhuo; Wu, Hongbo; Ren, Xiubao; Xie, Hua; Liu, Hua; Liu, Qiang; Yin, Xing; Luo, Xiaoyong; Chen, Jun; Zhang, Haiming; Guo, Zhiyuan; Ding, Cuimin; Jin, Xin; Sun, Rongli; Yang, Sheng

Safety of osimertinib in Chinese patients with non-small cell lung cancer: a multi-center, prospective, observational study

奥希替尼在中国非小细胞肺癌患者中的安全性:一项多中心、前瞻性、观察性研究

Zhong, Hua; Jiang, Shunjun; Yao, Wenxiu; Song, Xia; Lv, Dongqing; Zhu, Dan; Guo, Yubiao; Ding, Cuimin; Xue, Yingjie; Bai, Xiuli; Xiao, Liguo; Chen, Peifeng; Wang, Yan; Tian, Panwen; Lin, Gen; Li, Wen; Chen, Jun; Hu, Yanping; Xia, Bing; Wang, Ziping; Long, Hao; Yao, Weirong; Zhang, Haibo; Zhao, Qiong; Wang, Yuli; Lu, Liqin; Duan, Weiming; Xing, Ligang; Yang, Fujun; Chen, Yuan; Wei, Yang; Han, Baohui; He, Jianxing

Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study

卡瑞利珠单抗联合卡铂和培美曲塞作为晚期非鳞状非小细胞肺癌一线治疗:CameL随机3期研究的5年结果

Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Jin, Faguang; Gao, Hongjun; An, Guangyu; Ding, Cuimin; Jiang, Xiaodong; Xiong, Jianping; Zhou, Xiangdong; Hu, Sheng; Lu, Ping; Liu, Anwen; Guo, Shuliang; Huang, Jianjin; Zhu, Chengchu; Zhao, Jian; Gao, Beili; Chen, Yinglan; Hu, Chengping; Zhang, Jian; Zhang, Hongmei; Zhao, Hui; Wang, Zhigao; Ma, Xinjing; Shi, Wei